Dialysate Vascular Endothelial Growth Factor Is an Independent Determinant of Serum Albumin Levels and Predicts Future Withdrawal From Peritoneal Dialysis in Uremic Patients

Therapeutic Apheresis and Dialysis

Volumn 18, Issue 5, 2014, Pages 391-397

  Hazama, Takuma ^a   Fukami, Kei ^a   Yamagishi, Sho ichi ^a   Kusumoto, Takuo ^a   Sakai, Kazuko ^a   Adachi, Takeki ^a   Sonoda, Kazuhiro ^a   Kasuga, Syumon ^a   Ueda, Seiji ^a   Okuda, Seiya ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Hypoalbuminemia; Peritoneal dialysis; Pigment epithelium derived factor; Vascular endothelial growth factor; Withdrawal

Indexed keywords

ALBUMIN; HEMOGLOBIN; PIGMENT EPITHELIUM DERIVED FACTOR; VASCULOTROPIN; DIALYSIS FLUID; EYE PROTEIN; NERVE GROWTH FACTOR; PIGMENT EPITHELIUM-DERIVED FACTOR; SERINE PROTEINASE INHIBITOR; SERUM ALBUMIN; VASCULOTROPIN A;

ADULT; ALBUMIN BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIALYSATE LEVEL; END STAGE RENAL DISEASE; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; MALE; MIDDLE AGED; PERITONEAL DIALYSIS; PREDICTION; PROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT WITHDRAWAL; UREMIA; AGED; CHEMISTRY; COMPLICATION; KIDNEY FAILURE, CHRONIC; METABOLISM; PROCEDURES; REGRESSION ANALYSIS; TIME;

ADULT; AGED; DIALYSIS SOLUTIONS; EYE PROTEINS; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; NERVE GROWTH FACTORS; PERITONEAL DIALYSIS; PROSPECTIVE STUDIES; REGRESSION ANALYSIS; SERPINS; SERUM ALBUMIN; TIME FACTORS; UREMIA; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84909956089     PISSN: 17449979     EISSN: 17449987     Source Type: Journal    
DOI: 10.1111/1744-9987.12120     Document Type: Article

References (22)

1. Kaysen GA. Biological basis of hypoalbuminemia in ESRD. J Am Soc Nephrol 1998;9:2368-2376.
2. Mehrotra R, Duong U, Jiwakanon S etal. Serum albumin as a predictor of mortality in peritoneal dialysis: comparisons with hemodialysis. Am J Kidney Dis 2011;58:418-428.
3. John B, Tan BK, Dainty S, Spanel P, Smith D, Davies SJ. Plasma volume, albumin, and fluid status in peritoneal dialysis patients. Clin J Am Soc Nephrol 2010;5:1463-1470.
4. Koc Y, Unsal A, Ahbap E, Sakaci T, Yilmaz M. Clinical outcome of diabetic peritoneal dialysis patients and evaluation of factors affecting mortality: a single centre's experience from Turkey. J Ren Care 2011;37:94-100.
5. Sharma AP, Gupta A, Sharma RK, Agarwal DK, Sural S, Wardhe DJ. Does serum albumin at start of continuous ambulatory peritoneal dialysis (CAPD) or its drop during CAPD determine patient outcome? Adv Perit Dial 2000;16:119-122.
6. Wang Q, Bernardini J, Piraino B, Fried L. Albumin at the start of peritoneal dialysis predicts the development of peritonitis. Am J Kidney Dis 2003;41:664-669.
7. Mizuno M, Ito Y, Tanaka A etal. Peritonitis is still an important factor for withdrawal from peritoneal dialysis therapy in the Tokai area of Japan. Clin Exp Nephrol 2011;15:727-737.
8. Birmelé B, François M, Pengloan J etal. Death after withdrawal from dialysis: the most common cause of death in a French dialysis population. Nephrol Dial Transplant 2004;19:686-691.
9. Cueto-Manzano AM, Gamba G, Correa-Rotter R. Peritoneal protein loss in patients with high peritoneal permeability: comparison between continuous ambulatory peritoneal dialysis and daytime intermittent peritoneal dialysis. Arch Med Res 2001;32:197-201.
10. Han DS, Lee SW, Kang SW etal. Factors affecting low values of serum albumin in CAPD patients. Adv Perit Dial 1996;12:288-292.
11. Pecoits-Filho R, Araújo MR, Lindholm B etal. Plasma and dialysate IL-6 and VEGF concentrations are associated with high peritoneal solute transport rate. Nephrol Dial Transplant 2002;17:1480-1486.
12. Gao D, Zhao ZZ, Liang XH, Li Y, Cao Y, Liu ZS. Effect of peritoneal dialysis on expression of vascular endothelial growth factor, basic fibroblast growth factor and endostatin of the peritoneum in peritoneal dialysis patients. Nephrology (Carlton) 2011;16:736-742.
13. Tombran-Tink J, Chader GG, Johnson LV. PEDF: a pigment epithelium-derived factor with potent neuronal differentiative activity. Exp Eye Res 1991;53:411-414.
14. Kawaguchi Y, Ishizaki T, Imada A etal. Searching for the reasons for drop-out from peritoneal dialysis: a nationwide survey in Japan. Perit Dial Int 2003;23(Suppl 2):S175-177.
15. Adachi T, Fukami K, Yamagishi S etal. Decreased serum carnitine is independently correlated with increased tissue accumulation levels of advanced glycation end products in haemodialysis patients. Nephrology (Carlton) 2012;17:689-694.
16. Fukami K, Yamagishi SI, Okuda S. Development of enzyme-linked immunosorbent assay system for PEDF and its clinical utility. Curr Mol Med 2010;10:317-320.
17. Vonesh EF, Story KO, O'Neill WT. A multinational clinical validation study of PD ADEQUEST 2.0. PD ADEQUEST International Study Group. Perit Dial Int 1999;19:556-571.
18. De Vriese AS, Tilton RG, Stephan CC, Lameire NH. Vascular endothelial growth factor is essential for hyperglycemia-induced structural and functional alterations of the peritoneal membrane. J Am Soc Nephrol 2001;12:1734-1741.
19. Liu H, Ren JG, Cooper WL, Hawkins CE, Cowan MR, Tong PY. Identification of the antivasopermeability effect of pigment epithelium-derived factor and its active site. Proc Natl Acad Sci U S A 2004;101:6605-6610.
20. Yamagishi S, Nakamura K, Matsui T etal. Pigment epithelium-derived factor inhibits advanced glycation end product-induced retinal vascular hyperpermeability by blocking reactive oxygen species-mediated vascular endothelial growth factor expression. J Biol Chem 2006;281:20213-20220.
21. Fujimura T, Yamagishi S, Ueda S etal. Administration of pigment epithelium-derived factor (PEDF) reduces proteinuria by suppressing decreased nephrin and increased VEGF expression in the glomeruli of adriamycin-injected rats. Nephrol Dial Transplant 2009;24:1397-1406.
22. Selgas R, del Peso G, Bajo MA etal. Vascular endothelial growth factor (VEGF) levels in peritoneal dialysis effluent. J Nephrol 2001;14:270-274.